



WHY HEALTHCARE FUND?



Diversified Across The Pharma & Healthcare Sector



Long Term Wealth Creation From A Multi Decade Theme



An Evolving Theme With Significant Growth Potential



Enormous Opportunities For Advancement

INVESTMENT FRAMEWORK

Flexibility to invest across market capitalisation and style in selecting investment opportunities within this theme





Endeavour to maintain a concentrated portfolio of 30–40 stocks, in sectors like hospitals, diagnostics, specialty chemicals, medical equipment, insurance and other allied sub sectors


TOP 10 STOCK HOLDING *#

Stocks	May 2025	Jun 2025
Sun Pharmaceutical Industries Ltd.	11.41%	11.01%
Divi's Laboratories Ltd.	7.65%	8.53%
Aurobindo Pharma Ltd.	6.98%	6.67%
Glenmark Pharmaceuticals Ltd.	5.49%	6.38%
Apollo Hospitals Enterprise Ltd.	5.76%	6.37%
Cipla Ltd.	6.23%	6.18%
Lupin Ltd.	5.41%	5.18%
Dr. Reddy's Laboratories Ltd.	4.50%	4.36%
Krishna Institute of Medical Sciences Ltd.	4.15%	3.83%
Cohance Lifesciences Ltd.	3.88%	3.61%

TOP 10 SECTOR HOLDINGS *#

Sectors	May 2025	Jun 2025
Pharmaceuticals & Biotechnology	79.54%	78.77%
Healthcare Services	17.11%	17.43%
Chemicals & Petrochemicals	1.35%	1.50%
IT - Services	0.77%	0.78%
Healthcare Equipment & Supplies	0.58%	0.64%

MARKET CAPITALIZATION ^



PORTFOLIO PSYCHOGRAPHICS



Portfolio

Number of Stocks (Equity)	31
Top 10 Stock %	62.11%
Top 5 Sectors %	99.12%



Risk Ratios

Beta	0.97
Alpha	-3.93%
Portfolio Turnover Ratio	0.38 Times
Information Ratio	-0.85

FUND DETAILS

Fund Manager: Mr. Vrijesh Kasera (since July 02, 2018) & Mr. Tanmay Mehta[@] (since April 01, 2025)



SIP Amount:

Monthly and Quarterly: Minimum of ₹99/- (multiples of ₹1/- thereafter), minimum 5 in case of Monthly / Quarterly option.



Minimum Investment Amount: ₹5,000/- and in multiples of ₹1/- thereafter. Minimum Additional Application Amount: ₹1,000/- per application and in multiples of ₹1/- thereafter.



Plans and options: Regular Plan and Direct Plan with Growth Option and IDCW Option (Payout & Re-investment)



Allotment Date: 2nd July 2018



Benchmark: BSE Healthcare Index (TRI)



Net AUM: ₹ 2,785.12 Cr.



Risk Profile: Very High

^Pursuant to Clause 2.7 of Part IV of SEBI Master Circular dated June 27, 2024, the universe of ""Mid Cap"" shall consist of 101st to 250th company, Large Cap shall consist of top 100 companies, Small Cap shall consist of 251st and onwards companies in terms of full market capitalization.

#Pursuant to Clause 5.1 of SEBI Master Circular dated June 27, 2024. The sector(s)/stock(s)/issuer(s) mentioned in this presentation do not constitute any research report/recommendation of the same and the fund may or may not have any future position in these sector(s)/stock(s)/issuer(s) For complete portfolio of the scheme, please visit the website https://www.miraeassetmf.co.in/downloads/portfolio.

@Pursuant to notice cum addendum no. 21/2025, Fund Manager of the scheme has been changed with effect from April 01, 2025.

*Portfolio may or may not remain the same. For complete monthly portfolio, please visit the website: miraeassetmf.co.in/downloads/portfolio.

For further information about other schemes (product labelling and performance of the fund) please visit the website of the AMC: www.miraeassetmf.co.in

Disclaimer: Views expressed by Fund Manager cannot be construct to be a decision to invest. The Statements contained herein are based on current views and involve known and unknown risks and uncertainties. Whilst Mirae Asset Investment Managers (India) Private Limited (the AMC) shall have no responsibility/liability whatsoever for the accuracy or any use of reliance thereof of such information. The AMC, its associate or sponsors or group companies, its Directors or employees accept no liability for any loss or damage of any kind resulting out of the use of this document.

PRODUCT LABELLING

Mirae Asset Healthcare Fund

This product is suitable for investors who are seeking*

- To generate long term capital appreciation
- Investments in equity and equity related securities of companies benefitting directly or indirectly in Healthcare and allied sector in India

*Investors should consult their financial advisors if they are not clear about the suitability of the product





Distributed By









